AMICUS THERAPEUTICS INTERNATIONAL HOLDING LTD

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  -0.5%

  £98,377 → £97,882

• Net assets

  0%

  £154,885,240 → £154,841,601

• Employees

  —

  Not reported

• Operating profit

  +99.6%

  -£10,720,976 → -£43,639

• Profit before tax

  -100.2%

  £21,515,134 → -£43,639

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As detailed above Corporate support letters have been issued by Amicus Therapeutics Inc. which itself has been signed off as a going concern, further detail on going concern is contained in section 2.3 of notes to the financial statements below.”

Group structure

1. AMICUS THERAPEUTICS INTERNATIONAL HOLDING LTD · parent
   1. Amicus Therapeutics UK Limited 100% · United Kingdom · Commercialisation Ordinary of pharmaceutical products
   2. Amicus Therapeutics GmbH 100% · Germany · Commercialisation Ordinary of pharmaceutical products
   3. Amicus Therapeutics BV 100% · Netherlands · Other human health activities
   4. Amicus Therapeutics KK 100% · Japan · Commercialisation Ordinary of pharmaceutical products
   5. Amicus Therapeutics SAS 100% · France · Commercialisation Ordinary of pharmaceutical products
   6. Amicus Therapeutics S.r.l 100% · Italy · Commercialisation Ordinary of pharmaceutical products
   7. Amicus Therapeutics SP 100% · Spain · Commercialisation Ordinary of pharmaceutical products
   8. Amicus Therapeutics Canada Inc 100% · Canada · Commercialisation Ordinary of pharmaceutical products
   9. Amicus Therapeutics PTY 100% · Australia · Commercialisation Ordinary of pharmaceutical products
   10. Amicus Therapeutics ApS 100% · Denmark · Other human health activities
   11. Amicus Therapeutics Europe Limited 100% · Ireland · Commercialisation Ordinary of pharmaceutical products
   12. Amicus Therapeutics Switzerland GmbH 100% · Switzerland · Commercialisation Ordinary of pharmaceutical products

Significant events

• “The Group is also expanding with new products, in 2023, the European Commission (EC) and UK's Medicines and Healthcare Products Regulatory Agency (MHRA) fully approved Pombiliti + Opfolda for the treatment of late-onset Pompe disease (LOPD).”
• “In October 2023, Amicus Therapeutics Inc. entered into a loan agreement with Blackstone for $400m in order to repay existing group debt and provide adequate working capital for the future. As part of this agreement Amicus Therapeutics International Holding Ltd provided a first lien security interest over cash held in its bank account and its trade debtor balances.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

1

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.